Amaducci L, Lippi A
Dipartimento di Scienze Neurologiche e Psichiatriche, Università di Firenze.
Medicina (Firenze). 1990 Jul-Sep;10(3):213-27.
Statistics indicate that in Europe people over 65 years of age will be 23.5% at the beginning of the next century and prevalence of severe dementias is estimated to be 5% in this population group. Clinically, dementia is a syndrome characterized by memory loss, other cognitive dysfunctions and loss of ability for self-care. This organic syndrome, that can have many different causes, must be differentiated from other similar psychiatric disorders of the elderly such as the pseudo-dementias. The most important of these causes are Alzheimer's disease (AD) and vascular dementias. Other causes are infections, toxic and metabolic disorders, normal pressure hydrocephalus and head trauma. Many efforts are required in order to reach an accurate differential diagnosis, as 10-15% of the dementia syndromes are reversible if an appropriate therapy is applied. Because of its high frequency, AD is one of the most actively studied areas in dementia research. The specific causes of AD are still unknown, but recent case-control studies suggest the importance of risk factors such as familiarity and previous head trauma. Other hypotheses concern prion infections, aluminium toxicity and immunologic disorders. The most important findings of the last years however, concern biochemical alterations in Alzheimer's brains. After the first observations of Davies and Maloney (1976), who observed a reduction of choline acetyltransferase in cerebral cortex, many reports successively indicated the importance of deficiencies of the cholinergic systems in AD. Other neurotransmitter systems, such as the noradrenergic and the serotoninergic systems, were also found to be involved in AD. From these findings a rational therapeutic approach to the disease was proposed. Initially, the clinical trials employed physostigmin with uncertain results. Later, therapeutic attempts with choline, lecitine, acetylcarnitine and phosphatidilserine resulted more promising, at least in the initial phase. However, consistent data are not yet completely available. Finally, the management of AD also concerns problems of familiar education to the behavioural management of AD patients and the eventual possibilities of social assistance. Vascular dementia and Creutzfeldt-Jakob disease will also be discussed.
统计数据表明,在欧洲,65岁以上的人口在下个世纪初将占23.5%,而在这个人群中,重度痴呆症的患病率估计为5%。临床上,痴呆症是一种以记忆力丧失、其他认知功能障碍和生活自理能力丧失为特征的综合征。这种可能有多种不同病因的器质性综合征,必须与老年人其他类似的精神疾病如假性痴呆相鉴别。这些病因中最重要的是阿尔茨海默病(AD)和血管性痴呆。其他病因包括感染、中毒和代谢紊乱、正常压力脑积水和头部外伤。为了做出准确的鉴别诊断需要付出很多努力,因为如果采用适当的治疗方法,10%-15%的痴呆综合征是可逆的。由于其高发性,AD是痴呆症研究中最活跃的研究领域之一。AD的具体病因仍然未知,但最近的病例对照研究表明了诸如家族史和既往头部外伤等危险因素的重要性。其他假说涉及朊病毒感染、铝中毒和免疫紊乱。然而,过去几年最重要的发现涉及阿尔茨海默病患者大脑中的生化改变。在戴维斯和马洛尼(1976年)首次观察到大脑皮层中胆碱乙酰转移酶减少之后,许多报告相继指出胆碱能系统缺陷在AD中的重要性。还发现其他神经递质系统,如去甲肾上腺素能和5-羟色胺能系统也与AD有关。基于这些发现,提出了针对该疾病的合理治疗方法。最初,临床试验使用毒扁豆碱,结果不确定。后来,用胆碱、卵磷脂、乙酰肉碱和磷脂酰丝氨酸进行的治疗尝试至少在初始阶段更有前景。然而,尚未完全获得一致的数据。最后,AD的管理还涉及对AD患者行为管理的家属教育问题以及最终的社会援助可能性。血管性痴呆和克雅氏病也将进行讨论。